NICE approves gene-editing sickle cell therapy for NHS in England Exagamglogene autotemcel, also known as exa-cel, is now recommended for NHS use, reversing previous draft guidance.…
One-quarter of patients in pharmacogenomics trial have had prescriptions changed Around 25% of the 400 participants of the 'Progress programme' have been advised to change their prescription following genetic testing.…
Proposed National Pharmaceutical Agency on hold, says Scottish government Exclusive: The Scottish government has confirmed that the scoping phase in the development of a National Pharmaceutical Agency was paused before completion, with no next steps planned.…
More than 2,000 patients tested in UK’s first routine genotyping project for clopidogrel prescribing Exclusive: The genotyping project at NHS Tayside identified 2,300 patients, 29% of whom emerged as ‘poor’ or ‘intermediate’ CYP2C19-clopidogrel metabolisers.…
Lessons from testing 2,300 patients at the UK’s first CYP2C19 genotyping system Specialist clinical pharmacist Alex Matos explains what his team has learned in the two years since setting up the NHS Tayside project to genotype acute stroke patients with an indication for clopidogrel.…
Best practice principles for inclusive care of transgender and non-binary patients How pharmacists can best contribute to the care of transgender and non-binary patients, outlining additional considerations to ensure equitable care of this patient group.…
PJ view: Current testing for genetic variants risks undoing years of progress on health inequalities It is crucial that the NHS prioritises health equity as pharmacogenomic testing gains traction in day-to-day UK healthcare.…
Screening for gene variants should be broadened to reduce health inequalities, systematic review concludes Study authors have called for an extension to DPYD genetic testing in the UK, to include variants identified in people with African ancestry.…
NICE recommends phased roll out of genetic testing for clopidogrel prescribing In draft guidance, the National Institute for Health and Care Excellence said that testing could be rolled out to patients at higher risk of stroke recurrence first, while capacity is established.…
DOACs to be analysed as part of genetic biobank scheme Patients who report adverse effects from direct oral anticoagulants to the Yellow Card scheme may be contacted to provide a blood sample, from which data will then be added to a biobank for researchers to analyse.…
